MARKET

SONN

SONN

Sonnet BioTherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.260
-0.050
-2.16%
After Hours: 2.250 -0.01 -0.44% 19:13 04/09 EDT
OPEN
2.280
PREV CLOSE
2.310
HIGH
2.320
LOW
2.230
VOLUME
253.19K
TURNOVER
--
52 WEEK HIGH
16.20
52 WEEK LOW
1.810
MARKET CAP
39.68M
P/E (TTM)
-0.2547
1D
5D
1M
3M
1Y
5Y
Sonnet Biotherapeutics provides 2021 business update
Sonnet BioTherapeutics (SONN) provides a business update for the year and hinted at multiple clinical programs in 2021, as the company continues to make progress on its drug pipeline.The company
Seekingalpha · 03/30 13:13
Gold Fields, Danimer Scientific among premarket losers' pack
AeroCentury (ACY) -46% after filing petition for Chapter 11Wave Life Sciences (WVE) -27% on setback for Huntington’s disease trial (updated).Trxade Group (MEDS) -21% on Q4 earnings release.Vinco Ventures (BBIG) -16% on providing update to ZASH Global Media...
Seekingalpha · 03/30 12:42
Sonnet BioTherapeutics Provides 2021 Business Update
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its
Benzinga · 03/29 20:32
Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations
March 22, 2021 (ACCESSWIRE via COMTEX) -- PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the...
ACCESSWIRE · 03/22 11:00
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 03/05 13:15
Sonnet BioTherapeutics reports Q1 results
Sonnet BioTherapeutics (SONN): Q1 GAAP EPS of -$0.34.As of December 31, 2020, the company had $2.3 million cash on hand.Press Release
Seekingalpha · 02/16 13:44
Sonnet BioTherapeutics Q1 EPS $(0.34) Up From $(0.44) YoY
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.34) per share. This is a 22.73 percent increase over losses of $(0.44) per share from the same period last year.
Benzinga · 02/16 13:14
Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update
ACCESSWIRE · 02/16 13:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SONN. Analyze the recent business situations of Sonnet BioTherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SONN stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 23
Institutional Holdings: 708.55K
% Owned: 4.04%
Shares Outstanding: 17.56M
TypeInstitutionsShares
Increased
3
59.03K
New
7
50.07K
Decreased
1
79
Sold Out
8
55.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.53%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
Chairman/President/Chief Executive Officer/Director
Pankaj Mohan
Chief Financial Officer/Treasurer/Secretary
John Cross
Corporate Executive
Richard Adams
Chief Operating Officer
Mark Roberson
Corporate Executive
Rich Adams
Chief Technology Officer
Susan Dexter
Chief Scientific Officer
John Cini
Other
Manuel Dafonseca
Other
Richard Kenney
Other
Terence Rugg
Director
Nailesh Bhatt
Director
Albert Dyrness
Director
Donald Griffith
Director
Raghu Rao
No Data
  • All
  • Financials
  • Insiders
More
About SONN
Sonnet Biotherapeutics Holdings Inc, formerly Chanticleer Holdings, Inc., an oncology-focused biotechnology company. The Company is developing targeted biologic drugs with enhanced single or bispecific mechanisms.

Webull offers kinds of Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ:SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.